SCHEMBL4284928

SCHEMBL4284928

Cc1ccc2nc(CC(=O)CC3CCN(Cc4ccccc4)CC3)sc2c1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.58
ACHE P22303 4/20 0.58
DRD2 P14416 3/20 0.52
DRD4 P21917 3/20 0.52
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MGLL Q99685 1/20 0.47
AKR1B1 P15121 1/20 0.46
DRD3 P35462 1/20 0.45
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289978 0.85 BCHE (0.69) BCHEACHEDRD2DRD4ALDH1A1
Hydrochloric Acid SCHEMBL9381094 0.85 BCHE (0.69) BCHEACHEDRD2DRD4ALDH1A1
SCHEMBL4737224 0.82 DRD2 (0.54) BCHEACHEDRD2DRD4
SCHEMBL9382105 0.80 DRD2 (0.54) BCHEACHEDRD2DRD4
SCHEMBL221273 0.79 ACHE (0.70) BCHEACHEDRD2DRD4
SCHEMBL4696031 0.79 BCHE (0.55) BCHEACHEDRD2DRD4ALDH1A1
SCHEMBL4709902 0.78 DRD2 (0.51) BCHEACHEDRD2DRD4
SCHEMBL9381126 0.77 DRD2 (0.52) BCHEACHEDRD2DRD4
SCHEMBL4790504 0.77 BCHE (0.50) BCHEACHEDRD2DRD4
SCHEMBL4284930 0.76 BCHE (0.52) BCHEACHEALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009158646-A1 THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE ELIXIR PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed
EP-1898897-A2 METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS Sirtris Pharmaceuticals, Inc. (US) 2008-03-19 EP disclosed
EP-1877054-A2 NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF Sirtris Pharmaceuticals, Inc. (US) 2008-01-16 EP disclosed
EP-1853590-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2007-11-14 EP disclosed
WO-2007008548-A2 METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS SIRTRIS PHARMACEUTICALS, INC. (US) 2007-01-18 WO disclosed
WO-2006105440-A2 NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF SIRTRIS PHARMACEUTICALS, INC. (US) 2006-10-05 WO disclosed
WO-2006094235-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2006-09-08 WO disclosed
EP-0606248-A1 HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS Eisai Co., Ltd. (JP) 1994-07-20 EP disclosed